Updated to include a response from Ethicon.
A jury in Philadelphia found that Ethicon’s Gynemesh, Prolift and TVT-O meshes were defective, and that the company was negligent in manufacturing the devices, according to the report.
The plaintiff, Suzanne Emmett, was implanted with a Prolift pelvic mesh to treat pelvic organ prolapse, a TVT-O mesh as a treatment for incontinence and a Gynemesh implant, according to the Mesh News Desk report.
The verdict includes $25 million in punitive damages, $15 million in compensation and $1 million to Emmett’s husband, according to the report.
A spokesperson for Ethicon said in an email to MassDevice.com that it intends to appeal the decision and that it stands by its pelvic mesh products.
The company said that it believes that the decision contradicts evidence that its pelvic mesh devices were properly designed, and that it appropriately informed surgeons of known risks.
“Pelvic organ prolapse and stress urinary incontinence are serious and debilitating conditions with limited treatment options. Scientists from around the world who have conducted and reviewed independent research on pelvic mesh agree it is an important treatment option for some women. All surgeries to treat these conditions have risks. While we empathize with those who have experienced complications, many women with pelvic mesh see an improvement in their day to day lives,” Edwards said in its statement.
Last November, a state judge in Pennsylvania ordered a new trial in a suit alleging a that a woman was injured by Ethicon’s TVT-Secur pelvic mesh implant.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.